Shilpa Medicare (NSE:SHILPAMED) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHILPAMED Shilpa Medicare Ltd NSE:SHILPAMED
76 GF Score
Price ₹620.25
GF Value ₹387.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shilpa Medicare Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

NSE:SHILPAMED
76GF Score
Shilpa Medicare Ltd NSE:SHILPAMED
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for NSE:SHILPAMED:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shilpa Medicare Business Description

Other Exchanges 530549:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score

Get the complete analysis for NSE:SHILPAMED

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹620.25
Price
₹387.78
GF Value